Sanofi SA revealed on Thursday that its net sales in the first quarter of the fiscal year 2025 saw an annual rise of 10.8%, 9.7% at the constant exchange rate (CER), to reach €9.9 billion.
The company's net income, calculated according to the International Financial Reporting Standards (IFRS), came in at €1.8 billion, and its IFRS earnings per share (EPS) at €1.52. Meanwhile, its business net income increased by 15.9%, or 14.5% at CER, to €2.2 million, and its business EPS by 17%, 15.7% at CER, to €1.79. In the first quarter, Sanofi's gross profit jumped 14.2%, 11.3% at CER, to €7.7 billion.
"Underpinned by the growth in sales and business EPS, we confirm our 2025 guidance with the knowledge of the external environment we have today," Chief Executive Officer (CEO) Paul Hudson said.